跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
賴 峻毅
助理教授
臨床醫學研究所
https://orcid.org/0000-0002-8233-5466
電子郵件
jilai
nycu.edu
tw
網站
https://jillabnymu.wordpress.com/people/
h-index
h10-index
h5-index
624
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
431
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
186
引文
5
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2009
2024
每年研究成果
概覽
指紋
網路
研究成果
(46)
類似的個人檔案
(6)
指紋
查看啟用 Jiun-I Joseph Lai 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Breast Cancer
79%
Genetic Modification
58%
Taiwanese
56%
Tumor
51%
Marathoners
42%
Cyclin-dependent Kinase 4 (CDK4)
38%
Targeted Sequencing
37%
BRCA1, BRCA2
36%
EGFR mutation
33%
Erlotinib
28%
Polymorphism
28%
Acute Interstitial Pneumonitis
28%
Successful Treatment
28%
Sports Anemia
28%
Tumor Genomics
28%
FOLFOX
28%
Histone Deacetylase Inhibitor (HDACi)
28%
UBE2C
28%
Ubiquitin-proteasome System
28%
Deubiquitinating Enzyme
28%
ER+ Breast Cancer
28%
Asian Patients
28%
Breast Cancer Patients
25%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
25%
Triple-negative Breast Cancer
24%
Palbociclib
24%
Transcriptional Profiling
23%
Oxaliplatin
23%
Next-generation Sequencing
22%
Ultramarathon
21%
Taiwan
20%
HER2-positive
20%
Induced Pluripotent Stem Cells (iPSCs)
20%
Neutropenia
20%
Anemia
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Chemotherapy
19%
Immune Regulation
19%
FDA-approved Drugs
19%
Red Blood Cells
19%
Computed Tomography
19%
Respiratory Failure
19%
High Prevalence
18%
Stem Cell-derived
18%
ErbB2
18%
Non-small Cell Lung Cancer Patients
17%
Clinical Oncology
17%
Pulse Therapy
17%
Microsatellite Instability-high (MSI-H)
17%
Colorectal Cancer
16%
Biochemistry, Genetics and Molecular Biology
Prevalence
83%
Epidermal Growth Factor Receptor
60%
Genomics
58%
BRCA1
40%
Immunity
38%
Gene Expression Profiling
32%
Ubiquitin-Conjugating Enzyme
28%
Gene Mutation
25%
Enzyme
23%
Cancer Cell
23%
Next Generation Sequencing
22%
Induced Pluripotent Stem Cell
22%
Histone Deacetylase
22%
C-Reactive Protein
21%
Microsatellite Instability
16%
Homologous Recombination
16%
BRCA2
15%
Recombination Repair
15%
Heterochromatin Protein 1
14%
Interleukin 6
14%
Cohort Study
14%
Protein Kinases
14%
Tyrosine Kinase Inhibitor
14%
Friedreich's Ataxia
14%
Downregulation
14%
Xeroderma pigmentosum
14%
IKZF3
14%
Hemocyte
14%
Lipid
14%
Gene Repair
14%
Circulating Tumor DNA
14%
Heart Output
14%
N-Terminus
14%
Natriuretic Peptide
14%
Estrogen Receptor
14%
Immune-Related Gene
14%
Single Nucleotide Polymorphism
14%
Viscoelasticity
14%
Microsatellite
14%
Tetrapeptide
14%
Dioxygenase
14%
Allele
13%
Frataxin
12%
Messenger RNA
11%
Germline
11%
Germ Cell
11%
ERCC1
10%
Low Risk Population
10%
Exon
10%
Erythrocyte Count
9%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
77%
Prevalence
44%
Anemia
30%
Diseases
29%
Immunity
20%
Respiratory Failure
19%
Oxaliplatin
19%
BRCA1
18%
Biological Marker
17%
Elderly Patient
17%
Erythrocyte
17%
Next Generation Sequencing
16%
Neoadjuvant Chemotherapy
16%
Epidermal Growth Factor Receptor
14%
Neuroendocrine Carcinoma
14%
Acute Kidney Injury
14%
Pleura Effusion
14%
Pancreatitis
14%
Allograft
14%
Antigen Presenting Cell
14%
Pulmonary Rehabilitation
14%
Hip Fracture
14%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
14%
Pulse Rate
14%
Neuroendocrine Tumor
14%
Chemoradiotherapy
14%
Lipid Pneumonia
14%
Systemic Therapy
14%
FOLFOX
14%
Heterochromatin Protein 1
14%
Circulating Tumor DNA
14%
Natural Killer Cell
14%
Emergency Department
14%
Thymic Carcinoma
14%
Acute Appendicitis
14%
Acute Pancreatitis
14%
Homologous Recombination
14%
Rehabilitation Engineering
14%
Recombination Repair
14%
Situs Ambiguus
14%
Head Cancer
14%
Intensive Care Unit
14%
Computer Assisted Tomography
14%
Cetuximab
14%
Erlotinib
14%
Lung Cancer
14%
Tetrapeptide
14%
Abscess
14%
Cancer of Unknown Primary Origin
14%
